首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1593452

抗體藥物複合體市場規模、佔有率、成長分析、按產品類型、按連結器類型、按目標類型、按小分子藥物類型、按疾病類型、按地區 - 產業預測，2024-2031年

Antibody Drug Conjugates Market Size, Share, Growth Analysis, By Product, By Linker Type, By Target Type, By Payload Type, By Disease Type, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月12日 | 出版商:

SkyQuest | 英文 208 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

抗體藥物複合體（ADC）的全球市場規模在2022年為84.1億美元，從2023年的97億美元成長到2031年的300.9億美元，預計在預測期內（2024-2031年）年複合成長率為 15.2%。

全球癌症患者數量的快速增加以及對創新藥物的需求不斷成長將推動抗體藥物複合體（ADC）市場在未來幾年顯著成長。生物製藥研究投資的增加加上 ADC 開發技術的進步將進一步增強市場活力。此外，加快核准途徑的引進預計將顯著縮短 ADC 的上市時間並增加預測期內的銷售額。此外，個人化醫療的不斷成長趨勢及其日益普及預計將支持 ADC 市場的開拓。然而，該領域面臨開發成本高、毒性安全問題以及生物相似藥的激烈競爭等挑戰，可能會阻礙全球 ADC 公司的發展。隨著相關人員應對這一複雜的形勢，ADC 市場在技術創新和有效癌症治療的迫切需求的推動下提供了充滿希望的機會。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東、非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Roche Holding AG（Switzerland）
Daiichi Sankyo Company, Limited（Japan）
Gilead Sciences, Inc.（US）
Takeda Pharmaceutical Company Limited（Japan）
Pfizer Inc.（US）
Astellas Pharma Inc.（Japan）
AstraZeneca（UK）
ADC Therapeutics SA（Switzerland）
ImmunoGen, Inc.（US）
Zydus Group（India）
AbbVie Inc.（US）
Ambrx（US）
LegoChem Biosciences, Inc.（South Korea）
Byondis（Netherlands）
ProfoundBio（US）
RemeGen（China）
Sutro Biopharma, Inc.（US）
Lepu Biopharma Co., Ltd.（China）
Zymeworks Inc.（Canada）
Mersana Therapeutics（US）
Duality Biologics（China）
Lanova Medicines（China）
Exelixis, Inc.（US）
BioNeCure Therapeutics Inc.（US）
Tripartite Therapeutics, Inc.（US）

簡介目錄

Product Code: SQMIG35I2342

Global Antibody Drug Conjugates (ADC) Market size was valued at USD 8.41 billion in 2022 and is poised to grow from USD 9.70 billion in 2023 to USD 30.09 billion by 2031, growing at a CAGR of 15.2% in the forecast period (2024-2031).

The global surge in cancer cases and the rising demand for innovative pharmaceuticals are set to catalyze substantial growth in the antibody drug conjugates (ADCs) market in the coming years. Increased investments in biopharmaceutical research, coupled with advancements in ADC development technologies, will further enhance market dynamics. Moreover, the introduction of expedited approval pathways is expected to significantly reduce the time required for ADCs to reach the market, facilitating increased sales throughout the projected period. Additionally, the growing trend toward personalized medicine and its expanding adoption is likely to support the development of the ADC market. However, the sector faces challenges, including high developmental costs, safety concerns regarding toxicity, as well as stiff competition from biosimilars, which may hinder the growth of ADC companies globally. As stakeholders navigate these complexities, the ADC market presents a promising opportunity driven by innovation and the urgent need for effective cancer therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Drug Conjugates (Adc) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Drug Conjugates (Adc) Market Segmental Analysis

Global Antibody Drug Conjugates (ADC) Market is segmented on the product, linker type, target type, payload type, disease type, and region. By product, market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Other Products. By linker type, market is segmented into Cleavable Linkers and Non-Cleavable Linkers. By target type, market is segmented into HER2, CD22, CD30, and Other Target Types. By payload type, market is segmented into Monomethyl Auristatin E (MMAE), Calicheamicin, Maytansinoids, and Other Payload Types. By disease type, market is segmented into Breast Cancer, Blood Cancer, and Other Disease Types. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Antibody Drug Conjugates (Adc) Market

The rising global incidence of cancer is a significant market driver for the Global Antibody Drug Conjugates (ADC) market. As cancer continues to pose a formidable public health challenge, there is an escalating demand for innovative and targeted therapeutic options. This urgency has catalyzed extensive oncology research, leading to the development of advanced ADCs that combine the specificity of monoclonal antibodies with potent cytotoxic drugs. Consequently, the growing emphasis on personalized medicine and precise cancer management is expected to significantly enhance the adoption and sales of ADCs, creating robust growth prospects in this specialized therapeutic market segment.

Restraints in the Global Antibody Drug Conjugates (Adc) Market

The Global Antibody Drug Conjugates (ADC) market faces significant restraints due to the high operational costs associated with their manufacturing. The production of ADCs demands specialized equipment, advanced facilities, and a highly skilled workforce, all of which entail substantial capital investment. These elevated costs not only make the production process more expensive but also contribute to higher prices for end products, limiting accessibility and adoption in healthcare settings. Consequently, this financial burden restrains market growth by restricting investment from smaller companies and deterring potential market entrants, ultimately slowing down the overall development and expansion of the ADC market.

Market Trends of the Global Antibody Drug Conjugates (Adc) Market

The global Antibody Drug Conjugates (ADCs) market is witnessing a significant trend towards expanding applications beyond oncology, targeting various chronic diseases to broaden therapeutic horizons. As companies invest in developing ADCs for indications such as autoimmune disorders and infectious diseases, a lucrative landscape is emerging with ample opportunities for innovation. Additionally, the rising demand for combination therapies further propels ADCs into the spotlight, as their ability to enhance efficacy and improve patient outcomes positions them as valuable assets in holistic treatment approaches. This dual advancement is set to drive market growth, creating a dynamic and competitive environment for ADC manufacturers.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Value Chain Analysis
Technology Analysis
Patent Analysis
Pricing Analysis
Customer & Buying Criteria Analysis
PESTEL Analysis

Antibody Drug Conjugates Market, By Product

Market Overview
Kadcyla
Enhertu
Adcetris
Padcev
Trodelvy
Polivy
Other Products

Antibody Drug Conjugates Market, By Linker Type

Market Overview
Cleavable Linkers
Non-Cleavable Linkers

Antibody Drug Conjugates Market, By Target Type

Market Overview
HER2
CD22
CD30
Other Target Types

Antibody Drug Conjugates Market, By Payload Type

Market Overview
Monomethyl Auristatin E
Calicheamicin
Maytansinoids
Other Payload Types

Antibody Drug Conjugates Market, By Disease Type

Market Overview
Breast Cancer
Blood Cancer
Other Disease Types

Antibody Drug Conjugates Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ADC Therapeutics SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ImmunoGen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Group (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ambrx (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LegoChem Biosciences, Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Byondis (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ProfoundBio (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RemeGen (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sutro Biopharma, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lepu Biopharma Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mersana Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Duality Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lanova Medicines (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNeCure Therapeutics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tripartite Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments